Metabolic & Weight The Ozempic 'Resistance' Headline the Data Didn't Quite Earn
A new study identifies PAM-gene variants tied to weaker six-month HbA1c response to GLP-1 diabetes drugs, but the 'why Ozempic may not work' framing imports a weight-loss conclusion the paper doesn't reach, and the buried trials that used longer-acting GLP-1 drugs showed no carrier effect at all.
By Lena Marshall · June 7, 2026